Browse RMM Directory A-Z

${pdf_link}$

Abacavir - Patient Alert Card

Patient alert card for medicines containing Abacavir. This patient alert card should be used by patients who have been prescribed medicines containing Abacavir' and should carry with them at all times when taking this medicine.

${pdf_link}$

Abacavir alert card

Patient Alert Card

${pdf_link}$

Abacavir Alert Card

Important - Alert Card for Medicines Containing Abacavir.

${pdf_link}$

Abacavir Patient Alert Card

${pdf_link}$

Abacavir/Lamivudine 600 mg/300 mg film-coated tablets

Patient Alert Card

${pdf_link}$

Abacavir alert card

Patient Alert Card

${pdf_link}$

Abacavir -Risk minimisation Brochure

Abacavir hypersensitivity reaction Key risk minimisation points: Abacavir Hypersensitivity Reaction (HSR)

${pdf_link}$

Abacavir Alert Card

Important - Alert Card for Medicines Containing Abacavir.

${pdf_link}$

Educational material

Abacavir brochure risk minimisation

${pdf_link}$

Patient alert card

Abacavir patient alert card

${pdf_link}$

Abstral - UK Patient and Carer guide

Important risk minimisation information, on Abstral (fentanyl citrate) sublingual tablet, for patients prescribed Abstral and their carers

${pdf_link}$

Abstral - UK Pharmacist Guide

Important risk minimisation information, on Abstral (fentanyl citrate) sublingual tablet, for pharmacists

${pdf_link}$

Abstral - UK Prescriber Guide

Important risk minimisation information, on Abstral (fentanyl citrate) sublingual tablet, for physicians

${pdf_link}$

Patient Reminder Card

Alert card to be distributed to all patients (male and female) receiving acitretin each time the product is prescribed as a reminder of the required pregnancy prevention requirements/considerations.

${pdf_link}$

Pharmacist Checklist - Guidance for Dispensing Acitretin

Guidance document for pharmacists including a background on the risks of acitretin in addition to a list of information to be confirmed with the patient prior to dispensing.

${pdf_link}$

Prescriber Checklist / Acknowledgement Form for Prescribing Acitretin to Female Patients

Checklist/acknowledgement form for use when prescribing acitretin to female patients. This is intended to support discussion with the patient, present the key principles of the PPP and record that discussions have taken place by recording patient and prescriber signatures.

${pdf_link}$

Patient Alert Card

Alert card to be distributed to all patients (male and female) each time the product is prescribed as a reminder of the required pregnancy prevention requirements/considerations.

${pdf_link}$

Pharmacist Checklist - Guidance for dispensing Acitretin

Guidance document for pharmacists including a background on the risks in addition to a list of information to be confirmed with the patient prior to dispensing.

${pdf_link}$

'Prescriber Checklist/Acknowledgement Form for Prescribing Acitretin to Female Patients

Guidance document for pharmacists including a background on the risks in addition to a list of information to be confirmed with the patient prior to dispensing.

${pdf_link}$

Aclasta 5 mg solution for infusion - Patient Reminder Card

This Patient Reminder Card contains information regarding osteonecrosis of the jaw, a side effect that has been reported very rarely in patients receiving Aclasta. It also contains information regarding precautions that can be taken to reduce the risk of developing ONJ.

${pdf_link}$

Guide For Healthcare Professionals - Important Risk Minimisation Information on Potential Risk of Medication Errors

${pdf_link}$

Teva UK Patient/Carer Guide to the Safe Use of ACTIQ®

${pdf_link}$

Teva UK Pharmacist's Guide for Dispensing ACTIQ®

${pdf_link}$

Teva UK Physicians Guide for Prescribing ACTIQ®

${pdf_link}$

Patient Alert Card

${pdf_link}$

Liver Function Monitoring Scheme with Agomelatine

Liver function monitoring scheme with Agomelatine for the treatment of major depressive episodes in adults

${pdf_link}$

Patient information. Recommendations to avoid liver side effects

Important information for Patients about Agomelatine. Recommendations to avoid liver side effects

${pdf_link}$

Prescribers Guide

Prescribers guide. Agomelatine for the treatment of Major Depressive Episodes in Adults

${pdf_link}$

Agomelatine Flow Chart

Liver function monitoring scheme with Agomelatine for the treatment of major depressive episodes in adults

${pdf_link}$

Agomelatine patient information guide

Important information for patients about Agomelatine-recommendations to avoid liver side effects

${pdf_link}$

Agomelatine prescriber guide

Important safety information prescribers guide-Agomelatine- for the treatment of major depressive episodes in adults

${pdf_link}$

Checklist for Prescribers - Akizza 75 mcg 30 mcg tablets

Please use this checklist in conjunction with the Summary of Product Characteristics during combined hormonal contraceptive (CHC) consultations

${pdf_link}$

Important Information leaflet - Akizza 75mcg/30mcg Tablets

All women should understand the small risk of blood clots with the combined hormonal contraceptives; what other conditions increase the risk of a blood clot; the signs and symptoms of a blood clot; when you need to tell a healthcare professional that you are using a combined hormonal contraceptive.

${pdf_link}$

Patient Alert Card - Akizza 75mcg/30mcg Tablets

Important information for women about risk of blood clots with combined hormonal contraceptives.

${pdf_link}$

ALDURAZYME (LARONIDASE) HOME INFUSION GUIDE FOR CAREGIVERS

For hard copies please contact our medical information department at 0800 035 2525 or email [email protected]

${pdf_link}$

ALDURAZYME (LARONIDASE) HOME INFUSION GUIDE FOR HEALTH CARE PROFESSIONALS

For hard copies please contact our medical information department at 0800 035 2525 or email [email protected]

${pdf_link}$

Alitretinoin Patient Card

To be given by the dermatologist, specialist dermatology nurses, or prescribing GP to reinforce the key safety messages around risks

${pdf_link}$

Alitretinoin Pharmacist Check List

To be used as an aide memoire by pharmacists when dispensing oral retinoid medicines

${pdf_link}$

Prescriber Checklist / Acknowledgement Form for Prescribing Alitretinoin to Female Patients

To be used by the dermatologist, specialist dermatology nurse, or a prescribing GP with a special interest in dermatology to record the discussion of risks with the patient

${pdf_link}$

Rivastigmine Patch (Almuriva) - Instructions for use and patient diary - for patients

Instructions for use and patient diary

${pdf_link}$

Alunbrig (brigatinib) Patient Alert Card

Patient Alert Card

${pdf_link}$

Alzest instructions for use and patient diary Dec 2020

Instructions for use and patient diary

${pdf_link}$

Patient Alert Card - Ambrisentan 5 & 10 mg tab

This card contains important information about Ambrisentan. Please read this card carefully before starting your treatment with Ambrisentan. If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. If you are a woman of child-bearing age read this information carefully. Ambrisentan may harm unborn babies conceived before, during or soon after treatment. You must not take Ambrisentan if you are pregnant. Women of reproductive potential must use reliable contraception whilst taking Ambrisentan. Ambrisentan may cause liver injury. This card is produced as a service to patients by Cipla.

${pdf_link}$

Ambrisentan Patient Reminder Card

Patient Reminder Card for Ambrisentan

${pdf_link}$

Ambrisentan patient reminder card

${pdf_link}$

Patient Reminder Card

Important information for all patients taking Ambrisentan

${pdf_link}$

Amfexa Checklist 1

Checklist 1: checklist before prescribing Amfexa® 5 mg, 10 mg and 20 mg Tablets

${pdf_link}$

Amfexa Checklist 2

Checklist 2: checklist for monitoring of ongoing therapy with Amfexa® 5 mg, 10 mg and 20 mg Tablets

${pdf_link}$

Amfexa Considerations

Considerations when ending treatment with Amfexa ® 5 mg, 10 mg and 20 mg Tablets

${pdf_link}$

Amfexa Introduction

Due to the stimulant properties of dexamfetamine sulfate and the frequent presence of comorbidities associated with ADHD, it is important that dexamfetamine sulfate products be used consistently and only for the appropriate patients. The accompanying materials were developed by one of the dexamfetamine sulfate product manufacturers to facilitate awareness and adoption of recommendations for the use of dexamfetamine sulfate. It is recommended that these materials be used in conjunction with the SmPC for the individual product that is being prescribed.

${pdf_link}$

Amfexa patient and carers information UK

Information for parents and carers of patients prescribed Amfexa 5mg, 10mg and 20mgs tablets

${pdf_link}$

Amfexa Pharmacist Information

This sheet provides additional information for pharmacists on Amfexa® 5 mg, 10 mg and 20 mg Tablets (dexamfetamine sulfate).

${pdf_link}$

Amfexa Physician Information

A physician’s guide to prescribing Amfexa® 5 mg, 10 mg and 20 mg Tablets (dexamfetamine sulfate)

${pdf_link}$

Boys 2-18 years growth chart

This chart is mainly intended to assess the growth of school age boys. It combines data from the UK 1990 growth reference for children at birth and from 4 -18 years(1), with the WHO growth standard for children aged 2 years to 4 years(2). The growth of children under 2 years of age should be plotted on the more detailed UK-WHO 0-4 years growth charts.

${pdf_link}$

Chart for ongoing monitoring during Amfexa®(dexamfetamine sulfate) treatment

A form template according to prescribing information in more detail, growth, psychiatric and cardiovascular status should be regularly monitored

${pdf_link}$

Girls UK Growth chart 2-18 years

This chart is mainly intended to assess the growth of school age girls. It combines data from the UK 1990 growth reference for children at birth and from 4 -18 years(1), with the WHO growth standard for children aged 2 years to 4 years(2). The growth of children under 2 years of age should be plotted on the more detailed UK-WHO 0-4 years growth charts.

${pdf_link}$

Amgevita HCF Patient Reminder Card - Adults

${pdf_link}$

Amgevita HCF Patient Reminder Card - Paediatrics

${pdf_link}$

AMGEVITA Patient reminder card - adult

This card has important safety information about AMGEVITA. To request a copy of the patient alert card please contact Amgen medical information on 01223 436441 or by email to [email protected].

${pdf_link}$

AMGEVITA Patient reminder card - paediatric

This card has important safety information about AMGEVITA. To request a copy of the patient alert card please contact Amgen medical information on 01223 436441 or by email to [email protected].

${pdf_link}$

Patient Alert Card for Amiodarone Hydrochloride 200mg Tablets

${pdf_link}$

Patient Alert Card

${pdf_link}$

Prescriber Guide

${pdf_link}$

Apixaban Prescriber Guide

The educational pack is aimed at increasing awareness about the potential risk of bleeding/bleeding or thrombosis due to overdose or underdose during treatment with apixaban and providing guidance on how to manage that risk. This Prescriber Guide is not a substitute for the Apixaban Summary of Product Characteristics (SmPC). Please consult the SmPC for full prescribing information.

${pdf_link}$

Patient Alert Card

The patient alert card is aimed at increasing awareness about the potential risk of bleeding during treatment with apixaban. Patients prescribed apixaban will receive a patient alert card in the medicinal pack with the package leaflet. Please carry the patient alert card with you at all times and show it to every healthcare professional including pharmacists.

${pdf_link}$

Apixaban Patient Alert Card

${pdf_link}$

Apixaban Prescriber Guide

${pdf_link}$

Apixaban 2.5mg & 5mg Prescribers Guide

Apixaban 2.5mg & 5mg Prescribers Guide. This educational material is provided to further minimize the risk of bleeding that is associated with the use of apixaban and to guide healthcare professionals in managing that risk.

${pdf_link}$

Apixaban 2.5mg film-coated tablets patient alert card

${pdf_link}$

Apixaban 2.5mg film-coated tablets patient alert card (large)

${pdf_link}$

Apixaban 5mg film-coated tablets patient alert card

${pdf_link}$

Apixaban 5mg film-coated tablets patient alert card (large)

${pdf_link}$

Apixaban2.5mg and 5mg film-coated tablets - cover letter

Apixaban2.5mg and 5mg film-coated tablets - cover letter Outlining the indications for apixaban and the availability of risk minimisation materials.

${pdf_link}$

Apixaban Teva Patient Alert Card

${pdf_link}$

Apixaban Teva Prescriber Guide

${pdf_link}$

Apixaban (Zydus UK) Patient Alert Card

Patients prescribed Apixaban (Zydus UK) will receive a Patient Alert Card in the medication pack with the package leaflet. Please ensure you have read and understood the information in the card because it contains important safety information including the importance of taking Apixaban (Zydus UK) regularly as instructed by your treating Doctor, the main signs and symptoms of bleeding, and when to seek medical attention. Please carry the Patient Alert Card with you at all times and show it to every healthcare professional including pharmacists. Patient Alert Card is approved by MHRA in Aug-2024. If you would like to obtain hard copies of the Apixaban (Zydus UK) Patient Alert Card, please contact us via our Medical Information (Telephone: 0800 995 6034; Email: [email protected]) with your specific request. This is UK Only Risk minimisation materials.

${pdf_link}$

Apixaban (Zydus UK) Prescriber Guide

This risk minimisation material is for Apixaban (Zydus UK) 2.5 & 5 Mg film coated tablet. Please ensure that you are familiar with this material before prescribing Apixaban as it contains important safety information on the potential risk of bleeding during treatment and provides guidance on how to manage that risk. Prescriber Guide is approved by MHRA in Aug-2024. If you would like to obtain hard copies of the Apixaban (Zydus UK) Prescriber Guide and/or Patient Alert Card and/or SPCs, please contact us via our Medical Information (Telephone: 0800 995 6034; Email: [email protected]) with your specific request. This is UK Only Risk minimisation materials.

${pdf_link}$

Apixaban Patient Alert Card

${pdf_link}$

Apixaban Prescriber Guide

${pdf_link}$

Instructions for use for the Aranesp SureClick pre-filled pen

This booklet contains the instructions for use presented in a larger format and is intended for patients/caregivers with diminished eyesight. To request a printed version of this A4 booklet please contact Amgen Medical Information on 01223 436441 or by email to [email protected]

${pdf_link}$

Training Checklist for Self Administration - Pre-Filled Pen (Sureclick)®

This checklist is designed to ensure the patient/caregiver has received sufficient training with a demonstration device to enable confident and competent self-administration of the Aranesp SureClick® pre-filled pen at home. To request a printed version of the Training Checklist please contact Amgen Medical Information on 01223 436441 or by email to [email protected]

${pdf_link}$

ARAVA- Physician leaflet

For hard copies please contact our medical information department at 0800 035 2525 or email [email protected]

${pdf_link}$

ARAVA-Patient Leaflet

For hard copies, please contact medical information department at 0800 035 2525 or email [email protected].

${pdf_link}$

Arikayce Patient Alert Card

Patient alert card to notify patients on the adverse events and the procedure to deal with them.

${pdf_link}$

Aronix - Pharmacy Checklist

a short guide to help pharmacists determine whether your patient is suitable for Aronix, or whether he should be seen by a doctor for further advice. Use of the checklist is optional, and pharmacists should use their professional judgement to decide when and how to use it.

${pdf_link}$

Essential information for the supply of Aronix

This document provides key information to facilitate the assessment as to whether to supply Aronix, it also provides information on erectile dysfunction, its causes, risk factors, co-morbid links,management, treatment options, Aronix product information and pharmacist role in supporting the man.

${pdf_link}$

Aspaveli - Guide for Healthcare Professional

Important Information to communicate to patients/caregivers prior to prescribing ASPAVELI (pegcetacoplan)

${pdf_link}$

Aspaveli - Guide for Patient and Caregivers

This guide contains important information and safety considerations for pegcetacoplan, including the risk of serious infections (including meningitis) and guidance on self administration.

${pdf_link}$

Aspaveli - Patient Card

Important information for patients taking Aspaveli (pegcetacoplan)

${pdf_link}$

Glycopyrronium Bromide Tablets Patient Alert Card

The patient alert card is an aid which helps to provide the patient’s caregiver with essential information on the administration of Glycopyrronium bromide tablets and the management and minimisation of side effects. It is important that this card is given to the treating doctor to record guidance on dosing.

${pdf_link}$

Aubagio (teriflunomide) – Healthcare professional (HCP) – Education / Discussion Guide - Risk Minimisation Information for Healthcare Professionals

For hard copies please contact our medical information department at 0800 035 2525 or email [email protected]

${pdf_link}$

Aubagio (teriflunomide) – Patient Card - Risk Minimisation Information for Patients

For hard copies please contact our medical information department at 0800 035 2525 or email [email protected]

Risk Minimisation Materials

Abacavir

Aurobindo Pharma - Milpharm Ltd.

Dr. Reddy's Laboratories (UK) Ltd

Mylan

Abacavir+Lamivudine

Amarox Limited

Aurobindo Pharma - Milpharm Ltd.

Dr. Reddy's Laboratories (UK) Ltd

Ranbaxy (UK) Limited a Sun Pharmaceutical Company

Abstral

Grunenthal Meds

Acitretin

Genus Pharmaceuticals

Morningside Healthcare Ltd

Aclasta

Sandoz Limited

Acopair

Mylan

Actiq

Teva Pharma B.V.

Agamree

Santhera (UK) Limited

Agomelatine

Aristo Pharma Limited

Zentiva

Akizza

Morningside Healthcare Ltd

Aldurazyme

SANOFI

Alitretinoin

Ennogen IP Ltd

Almuriva

Sandoz Limited

Alunbrig

Takeda UK Ltd

Alzest

Dr. Reddy's Laboratories (UK) Ltd

Ambrisentan

Cipla EU Ltd

Dr. Reddy's Laboratories (UK) Ltd

Mylan

Zentiva

Amfexa

Medice UK LTD

Amgevita

Amgen Ltd

Amiodarone

Ennogen Pharma Ltd

Apixaban

Amarox Limited

axunio Pharma GmbH

Mylan

Sandoz Limited

Teva UK Limited

Zydus Pharmaceuticals UK Ltd

Apixaban film-coated tablets

Aurobindo Pharma - Milpharm Ltd.

Aranesp

Amgen Ltd

Arava

SANOFI

Arikayce

Insmed Limited

Aronix

Dr. Reddy's Laboratories (UK) Ltd